SouthernWorldwide.com – The chief executive of a prominent Democratic fundraising platform is scheduled to face intense questioning from House lawmakers amid escalating concerns about whether the organization misled Congress regarding alleged donor fraud.
Regina Wallace-Jones, CEO of ActBlue, is set to testify before the House Administration Committee. This hearing is anticipated to be highly charged as a long-standing congressional investigation into how ActBlue vets overseas donors reaches a critical juncture.
This will mark Wallace-Jones’ first public statement addressing the fraud allegations. In a significant development, she announced just hours before the hearing that she would exercise her Fifth Amendment right against self-incrimination when questioned by the committee. This decision was detailed in an op-ed published in The Washington Post.
ActBlue representatives have consistently refuted claims of providing false statements to Congress. They have also asserted that the Republican-led investigation is politically motivated.
Earlier this week, an attorney for Wallace-Jones formally requested that House Committee Chairman Bryan Steil, R-Wis., issue a subpoena for her testimony. This request came weeks after Wallace-Jones had voluntarily agreed to appear before the committee on June 10.
It is expected that House Judiciary Committee Chairman Jim Jordan, R-Ohio, and House Oversight Committee Chairman James Comer, R-Ky., who have been involved in the ActBlue probe, will be permitted to join the committee to question Wallace-Jones.
Chairman Steil has characterized the hearing as part of a broader congressional effort to prevent foreign financial influence in the political arena.
The House Administration Committee has been scrutinizing ActBlue since 2023. Their focus has been on the payment processor’s fraud prevention measures and its handling of overseas donations, which may have been improperly channeled into U.S. elections.
It is important to note that nonresident foreign nationals are generally prohibited from making political contributions to federal and state candidates, their committees, and political action committees.
Wednesday’s hearing follows an acceleration of Republican scrutiny on ActBlue. This intensified focus was prompted by a report in The New York Times earlier this year. The report indicated that ActBlue’s former outside counsel had warned Wallace-Jones that she might have made false statements to Steil’s committee regarding its fraud screening practices.
According to the report, the attorneys found that some of the anti-fraud measures described to congressional investigators were not consistently implemented as stated. ActBlue did not immediately correct these statements with the House Administration Committee, even after internally enhancing its donor screening practices.
The payment processor later acknowledged that certain fraud prevention practices had been strengthened in a letter sent to Steil’s committee in June 2025.
Republicans have contended that the discrepancy between ActBlue’s statements to Congress and its internal operational practices was likely “an attempt to avoid negative attention,” as stated by Steil in a letter to Wallace-Jones on Tuesday.
Steil has been a vocal critic of ActBlue personnel for their refusal to fully cooperate with the committee’s investigation. Notably, five current and former ActBlue employees invoked their Fifth Amendment right against self-incrimination a total of 146 times when their testimony was subpoenaed by the committee.
The Republican-led panel has also broadened its investigation into ActBlue beyond Wallace-Jones. Earlier in June, Steil requested that five members of ActBlue’s Board of Directors participate in transcribed interviews. These interviews are intended to discuss their roles in the organization’s response to congressional scrutiny and how they addressed a significant number of departures within ActBlue amidst internal turmoil over whether Wallace-Jones had misled Congress.
The New York Times also reported that two unions affiliated with ActBlue had cautioned the board about a “growing pattern of volatility and toxicity” within leadership. This included allegations of retaliation against a whistleblower.
